Lunesta and Bupropion Interaction: Safety, Risks, and Clinical Guidance

Why This Combination Comes Up in Practice

Bupropion is one of the most commonly prescribed antidepressants in the United States, with over 29 million dispensed prescriptions in 2022 according to ClinCalc drug utilization data. A well-known side effect is insomnia, reported in 11% to 20% of patients in clinical trials documented in the FDA-approved bupropion label [1]. Clinicians frequently add a short-acting hypnotic to manage this sleep disruption.

Eszopiclone, the S-isomer of zopiclone, earned FDA approval in 2004 for insomnia without a restriction on duration of use [2]. That distinction matters. Unlike many Z-drugs, it was studied in trials lasting six months, giving prescribers more comfort with longer co-administration alongside antidepressants. A 2006 study by Fava et al. in Sleep (N=545) found that eszopiclone 3 mg co-administered with fluoxetine significantly improved both sleep and depressive symptoms compared to fluoxetine plus placebo [3]. While that trial used fluoxetine rather than bupropion, it established the clinical pattern of pairing eszopiclone with antidepressant therapy.

The question patients ask is direct: will these two drugs interact? The answer requires separating pharmacokinetic (PK) effects from pharmacodynamic (PD) effects.

Pharmacokinetic Profile: Minimal Metabolic Overlap

Eszopiclone undergoes hepatic oxidation and demethylation. CYP3A4 is the primary enzyme responsible for its biotransformation, with CYP2E1 playing a secondary role [2]. The eszopiclone FDA label states that co-administration with ketoconazole, a potent CYP3A4 inhibitor, increased eszopiclone AUC by 2.2-fold [2]. That finding confirms CYP3A4 as the rate-limiting pathway.

Bupropion is metabolized by CYP2B6 to its active metabolite hydroxybupropion [1]. Bupropion itself is a strong inhibitor of CYP2D6, raising plasma levels of CYP2D6 substrates by 5- to 6-fold in some cases. The FDA label for bupropion documents a 5.1-fold increase in desipramine AUC when the two drugs were co-administered [1].

Here is the critical point. CYP2D6 does not play a meaningful role in eszopiclone clearance. No published pharmacokinetic study has identified CYP2D6 as a contributor to eszopiclone metabolism [2]. This means bupropion's strong CYP2D6 inhibition should not raise eszopiclone plasma concentrations to a clinically significant degree.

A 2009 comprehensive review in the Journal of Clinical Pharmacology by Hesse et al. mapped the inhibition profiles of common psychotropic drugs and confirmed that bupropion's enzyme effects are "essentially confined to CYP2D6, with negligible activity at CYP1A2, CYP2C9, CYP2C19, and CYP3A4" [4]. This selectivity is what makes the eszopiclone-bupropion PK interaction low-risk.

Pharmacodynamic Concerns: CNS Depression and Seizure Threshold

The PD interaction deserves more attention than the PK interaction. Both drugs act on the central nervous system through different mechanisms, and their combined effects on arousal, cognition, and seizure threshold require careful consideration.

Eszopiclone binds to the alpha subunit of the GABA-A receptor complex, enhancing chloride conductance and producing sedation, anxiolysis, and muscle relaxation [2]. Bupropion inhibits the reuptake of norepinephrine and dopamine, producing stimulatory and activating effects [1]. In theory, these opposing pharmacodynamic profiles could partially offset each other. Patients may experience less next-morning sedation from eszopiclone when bupropion's activating properties are present.

The seizure question is more nuanced. Bupropion carries a dose-dependent seizure risk. The incidence at doses up to 450 mg/day of the immediate-release formulation was approximately 0.4% (4 per 1,000) in premarketing trials [1]. At doses between 450 and 600 mg/day, the rate climbed to approximately 4%, prompting the FDA to set a maximum recommended dose of 450 mg/day [1].

GABA-A agonists are generally anticonvulsant. Benzodiazepines are used to treat status epilepticus specifically because of this property. Eszopiclone, as a GABA-A positive allosteric modulator, may theoretically provide a modest protective effect against bupropion-induced seizure risk [5]. However, no clinical trial has tested this hypothesis directly, and clinicians should not rely on eszopiclone as seizure prophylaxis.

Dr. Andrew Krystal, who led several key eszopiclone trials at Duke University, noted in a 2006 Sleep publication that "the co-administration of eszopiclone with antidepressant therapy appears to produce additive benefits on sleep without evidence of pharmacokinetic interference or increased adverse events" [3].

Severity Rating Across Drug Interaction Databases

Different DDI databases classify this interaction with varying levels of concern. A comparative look is useful for clinicians.

The Lexicomp database categorizes the combination as "Monitor Therapy" (Category C), indicating the interaction is recognized but manageable with standard clinical vigilance [6]. Clinical Pharmacology (Elsevier) rates it as a moderate interaction, primarily on PD grounds related to additive CNS depression. Micromedex assigns a similar moderate severity rating.

None of the major DDI databases classify eszopiclone plus bupropion as "Avoid Combination" or "Contraindicated." This is consistent with the pharmacokinetic data showing no meaningful metabolic overlap.

The American Academy of Sleep Medicine (AASM) clinical practice guideline for pharmacologic treatment of chronic insomnia (2017) conditionally recommended eszopiclone as a treatment option, noting that clinicians should "consider the patient's comorbidities and concomitant medications" when selecting a hypnotic [7]. The guideline did not single out bupropion as a specific concern with eszopiclone.

Monitoring Parameters for the Combination

Clinicians prescribing both drugs should monitor for specific outcomes across several domains. Sedation and next-morning impairment are the primary safety endpoints.

The FDA issued a 2014 safety communication lowering the recommended starting dose of eszopiclone from 2 mg to 1 mg after data showed that blood levels of eszopiclone at 7.5 hours post-dose could impair driving, memory, and coordination [8]. In a pharmacokinetic study cited by the FDA, 50% of subjects who took eszopiclone 3 mg had blood levels above 12 ng/mL at approximately 7.5 hours, a threshold associated with measurable psychomotor impairment [8].

For patients also taking bupropion, monitor these parameters:

Daytime somnolence. Ask about morning grogginess, especially during the first two weeks of combination therapy. If impairment is reported, the eszopiclone dose should be reduced to 1 mg.

Sleep architecture changes. Bupropion can suppress REM sleep, while eszopiclone tends to preserve or modestly increase REM duration [3]. Patients may report vivid dreams or changes in dream content.

Mood and activation. Bupropion-induced agitation or anxiety may worsen in patients whose sleep is not adequately controlled. Paradoxically, untreated insomnia is a risk factor for suicidal ideation in depressed patients. The STAR*D trial (N=4,041) found that insomnia was present in 84.7% of participants with major depressive disorder at baseline [9].

Seizure risk factors. Screen for concurrent risk factors including eating disorders, alcohol withdrawal, benzodiazepine withdrawal, history of head trauma, and concurrent use of other seizure-threshold-lowering medications.

Dose Adjustments and Prescribing Recommendations

No routine dose adjustment of either drug is required based on their pharmacokinetic profiles alone. The clinical approach focuses on starting low and monitoring.

For eszopiclone, the FDA-recommended starting dose is 1 mg at bedtime for all adults, with escalation to 2 or 3 mg based on clinical response [2]. In patients aged 65 and older, the maximum recommended dose is 2 mg. Hepatic impairment (Child-Pugh class B or C) also warrants a starting dose of 1 mg with a maximum of 2 mg [2].

For bupropion, dosing depends on the formulation. The extended-release (XL) formulation is typically initiated at 150 mg once daily and increased to 300 mg once daily after four days if tolerated [1]. The 300 mg XL dose is the standard target for major depressive disorder. Doses above 450 mg/day are not recommended due to the disproportionate increase in seizure risk.

The American Psychiatric Association's 2010 practice guideline for treatment of major depressive disorder acknowledged that "insomnia persisting despite adequate antidepressant treatment may warrant adjunctive pharmacotherapy with a sedative-hypnotic" [10].

One practical timing consideration: bupropion XL should be taken in the morning, and eszopiclone immediately before bedtime. This separation of approximately 14 to 16 hours means peak plasma concentrations of the two drugs rarely overlap. Bupropion XL reaches Tmax at approximately 5 hours [1], while eszopiclone reaches Tmax at approximately 1 hour [2].

Special Populations and Risk Stratification

Certain patient groups require extra caution with this combination. Older adults metabolize eszopiclone more slowly, with a mean elimination half-life of approximately 9 hours compared to 6 hours in younger adults [2]. Bupropion's hydroxybupropion metabolite also accumulates to a greater degree in older patients, with the metabolite's AUC approximately 2-fold higher than in younger adults [1].

Patients with hepatic impairment face compounded risk. Both drugs undergo hepatic metabolism. Eszopiclone's AUC increased 2-fold in subjects with severe hepatic impairment [2]. Bupropion's half-life extended from 21 hours to 34 hours in patients with alcoholic liver disease [1]. If both drugs are needed in a patient with liver disease, eszopiclone should not exceed 2 mg and bupropion should be prescribed at reduced frequency (e.g., 150 mg every other day for the SR formulation).

Patients with a personal or family history of seizures represent the highest-risk group. Bupropion is relatively contraindicated in patients with a seizure disorder [1]. Adding any CNS-active medication in this population requires documented risk-benefit analysis. If a hypnotic is needed, consider whether melatonin receptor agonists (ramelteon) or orexin receptor antagonists (suvorexant, lemborexant) might carry lower interaction potential.

When to Choose an Alternative Hypnotic

The eszopiclone-bupropion combination is appropriate for many patients, but alternatives deserve consideration in specific scenarios.

If the patient takes a strong CYP3A4 inhibitor (e.g., ketoconazole, itraconazole, clarithromycin, ritonavir) in addition to bupropion, eszopiclone exposure could increase substantially. The FDA label notes a 2.2-fold AUC increase with ketoconazole alone [2]. Adding a second interacting drug to this baseline elevation may push eszopiclone levels into a range associated with prolonged sedation and complex sleep behaviors.

In that scenario, switching to suvorexant or lemborexant may be preferable. Suvorexant is metabolized by CYP3A4 (and therefore shares the ketoconazole interaction), but lemborexant has a shorter half-life of approximately 17 to 19 hours and lower accumulation potential in some patients [11]. Ramelteon, metabolized primarily by CYP1A2, avoids the CYP3A4 and CYP2D6 pathways entirely and may be the cleanest option from an interaction standpoint [12].

For patients on bupropion who need only short-term sleep support (fewer than two weeks), low-dose doxepin (Silenor, 3 to 6 mg) is another option. Its primary pharmacologic effect at these doses is histamine H1 antagonism rather than serotonin/norepinephrine reuptake inhibition, and it has minimal CYP2D6 interaction liability at the 6 mg dose [13].

Patient Counseling Points

Patients prescribed both medications need specific instructions. Take eszopiclone only when you can dedicate 7 to 8 full hours to sleep. Do not take it with or immediately after a high-fat meal, as fat delays absorption and reduces peak concentration by approximately 21% [2]. Avoid alcohol entirely while taking both medications. Alcohol increases CNS depression with eszopiclone and independently lowers the seizure threshold, compounding bupropion's risk.

Report any unusual nighttime behaviors (sleepwalking, sleep-driving, making phone calls while not fully awake) immediately. The FDA requires a boxed warning on all Z-drugs, including eszopiclone, regarding complex sleep behaviors following post-marketing safety data published in 2019 [14]. The reported incidence is rare but the consequences can be severe, including fatal outcomes.

If you experience a seizure, loss of consciousness, or involuntary muscle jerking, seek emergency care and discontinue bupropion until evaluated. The eszopiclone starting dose recommended by the FDA since 2014 is 1 mg, not 2 mg or 3 mg [8].